Page 46 - GTM-2-4

Global Translational Medicine The research advances in HPV integration

nanopore MinION sequencer without error correction. https://doi.org/10.1016/j.ygyno.2018.06.014
Front Genet, 11: 660.
84. Chen L, Dong B, Gao H, et al., 2020, HPV-16 E2/E6 and
https://doi.org/10.3389/fgene.2020.00660 POU5F1B as biomarkers to determine cervical high-grade
squamous lesions and more. J Inflamm Res, 13: 813–821.
74. Schultzhaus Z, Wang Z, Stenger D, 2021, CRISPR-based
enrichment strategies for targeted sequencing. Biotechnol https://doi.org/10.2147/JIR.S278911
Adv, 46: 107672.
85. Morgan IM, DiNardo LJ, Windle B, 2017, Integration of
https://doi.org/10.1016/j.biotechadv.2020.107672 human papillomavirus genomes in head and neck cancer: Is
it time to consider a paradigm shift? Viruses, 9: 208.
75. Iden M, Tsaih SW, Huang YW, et al., 2021, Multi-omics
mapping of human papillomavirus integration sites https://doi.org/10.3390/v9080208
illuminates novel cervical cancer target genes. Br J Cancer, 86. Zhou L, Qiu Q, Zhou Q, et al., 2022, Long-read sequencing
125: 1408–1419. unveils high-resolution HPV integration and its oncogenic
https://doi.org/10.1038/s41416-021-01545-0 progression in cervical cancer. Nat Commun, 13: 2563.
76. Artesi M, Hahaut V, Cole B, et al., 2021, PCIP-seq: https://doi.org/10.1038/s41467-022-30190-1
Simultaneous sequencing of integrated viral genomes and 87. Hoyer H, Mehlhorn G, Scheungraber C, et al., 2021,
their insertion sites with long reads. Genome Biol, 22: 97. Evaluation of integrated HPV DNA as individualized
https://doi.org/10.1186/s13059-021-02307-0 biomarkers for the detection of recurrent CIN2/3 during
post-treatment surveillance. Cancers (Basel), 13: 3309.
77. Madsen EB, Höijer I, Kvist T, et al., 2020, Xdrop: Targeted
sequencing of long DNA molecules from low input samples https://doi.org/10.3390/cancers13133309
using droplet sorting. Hum Mutat, 41: 1671–1679. 88. Shin HJ, Joo J, Yoon JH, et al., 2014, Physical status of human
https://doi.org/10.1002/humu.24063 papillomavirus integration in cervical cancer is associated
with treatment outcome of the patients treated with
78. World Health Organization, 2021, WHO Guideline for radiotherapy. PLoS One, 9: e78995.
Screening and Treatment of Cervical Pre-Cancer Lesions for
Cervical Cancer Prevention. 2 ed. Geneva: World Health https://doi.org/10.1371/journal.pone.0078995
nd
Organization. 89. Meng Y, Lin S, Zhou Y, et al., 2022, RAB2A promotes
79. Murdaca G, Calamaro P, Lantieri F, et al., 2018, HLA-G cervical cancer progression as revealed by comprehensive
expression in gastric carcinoma: Clinicopathological correlations analysis of HPV integration and proteome in longitudinal
and prognostic impact. Virchows Arch., 473: 425–433. cervical samples. Clin Transl Med, 12: e767.
https://doi.org/10.1007/s00428-018-2379-0 https://doi.org/10.1002/ctm2.767
80. Cancer Genome Atlas Research Network, Albert Einstein 90. Sher YP, Lee C, Liu SY, et al., 2018, A therapeutic vaccine
College of Medicine, Analytical Biological Services, et al., targeting HPV E6/E7 with intrinsic Toll-like receptor 2
2017, Integrated genomic and molecular characterization of agonist activity induces antitumor immunity. Am J Cancer
cervical cancer. Nature, 543: 378–384. Res, 8: 2528–2537.
htps://doi.org/10.1038/nature21386 91. Cory L, Chu C, 2014, ADXS-HPV: A therapeutic Listeria
vaccination targeting cervical cancers expressing the HPV
81. Liu L, Ying C, Zhao Z, et al., 2018, Identification of reliable E7 antigen. Hum Vaccin Immunother, 10: 3190–3195.
biomarkers of human papillomavirus 16 methylation in
cervical lesions based on integration status using high- https://doi.org/10.4161/hv.34378
resolution melting analysis. Clin Epigenetics, 10: 10. 92. Salinas-Montalvo AM, Supramaniam A, McMillan NA,
https://doi.org/10.1186/s13148-018-0445-8 et al., 2021, RNA-based gene targeting therapies for human
papillomavirus driven cancers. Cancer Lett, 523: 111–120.
82. Verhoef VM, Bosgraaf RP, van Kemenade FJ, et al., 2014,
Triage by methylation-marker testing versus cytology https://doi.org/10.1016/j.canlet.2021.10.005
in women who test HPV-positive on self-collected 93. Ojesina AI, Lichtenstein L, Freeman SS, et al., 2014,
cervicovaginal specimens (PROHTECT-3): A randomised Landscape of genomic alterations in cervical carcinomas.
controlled non-inferiority trial. Lancet Oncol, 15: 315–322. Nature, 506: 371–375.
https://doi.org/10.1016/S1470-2045(14)70019-1 https://doi.org/10.1038/nature12881
83. Rogeri CD, Silveira HCS, Causin RL, et al., 2018, Methylation 94. Zhao JW, Zheng W, Wang LQ, et al., 2023, Human
of the hsa-miR-124, SOX1, TERT, and LMX1A genes as papillomavirus (HPV) integration signature in cervical
biomarkers for precursor lesions in cervical cancer. Gynecol lesions: Identification of MACROD2 gene as HPV hot spot
Oncol, 150: 545–551. integration site. Arch Gynecol Obstet, 307: 1115–1123.

Volume 2 Issue 4 (2023) 20 https://doi.org/10.36922/gtm.2034